U.S. top court rejects Helsinn over anti-nausea drug patent in win for Teva
WASHINGTON (Reuters) - The U.S. Supreme Court on Tuesday refused to revive Swiss drug company Helsinn Healthcare S.A.'s patent on the lucrative anti-nausea drug Aloxi in a victory for Teva Pharmaceutical Industries, which launched a generic version of it last year. The nine justices unanimously upheld a lower court ruling that had canceled Helsinn's patent on Aloxi for violating a provision in U.S. patent law that forbids sales of an invention before applying for a patent. Teva began selling its generic version of the drug in March 2018 ...
Click
To Read Full Article